Grant: Banting Postdoctoral Fellowship Program
McGill University
$140,000.00
Leveraging large-scale sequencing to identify and validate genetic influences of movement disorders.
EF 2021-22
Résumé
Movement disorders are a subcategory of neurodegenerative diseases caused by progressive deterioration of brain cells and resulting in muscle weakness, abnormal movements, and/or tremors. The disorders may be rarer, but fatal, such as amyotrophic lateral sclerosis (ALS) or more common such as essential tremor (ET), which affects up to 5% of older adults. Currently, these conditions lack treatment options and much remains to be understood regarding an individual's genetic susceptibility to the diseases. Here, I aim to use large DNA sequencing datasets to identify new movement disorder-associated genes, by comparing DNA mutation frequencies in disease cases versus healthy control samples.
To study ALS, I will apply rigorous statistical approaches to the two largest DNA sequencing datasets of ALS patients. In addition to taking an agnostic approach looking at all genes in the genome, I will investigate sets of genes known to contribute to molecular pathways associated with ALS. Further, I will use our understanding of which regions of genes may have greater functional implications when mutated to guide my analyses. All novel genetic findings will be validated with cell-based experiments.
We are also currently initiating a consortium to create the largest DNA sequencing datasets yet available for ET by partnering with international research collaborators that also study patients with the disorder. I will take a leading role in this initiative and, following the DNA sequencing, I will apply similar analysis methods as described above in regards to ALS to identify and validate new genes contributing to the risk of ET.
The results of this study will provide further insights into what may be causing movement disorders on a molecular level, allowing for the identification of new treatment targets and genetic-sequencing-based early diagnostic and risk assessment tools. It is our goal to improve the diagnosis, prognosis, and outcomes for individuals facing movement disorders.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
453910
Name
Dilliott Allison A
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Leveraging large-scale sequencing to identify and validate genetic influences of movement disorders.
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Amyotrophic Lateral Sclerosis; Bioinformatics; Essential Tremor; Functional Gene Sets; Gene Burden Analysis; Genetics; Movement Disorders; Neurodegenerative Disease; Next-Generation Sequencing; Rare Variant Enrichment
Abstract
Movement disorders are a subcategory of neurodegenerative diseases caused by progressive deterioration of brain cells and resulting in muscle weakness, abnormal movements, and/or tremors. The disorders may be rarer, but fatal, such as amyotrophic lateral sclerosis (ALS) or more common such as essential tremor (ET), which affects up to 5% of older adults. Currently, these conditions lack treatment options and much remains to be understood regarding an individual's genetic susceptibility to the diseases. Here, I aim to use large DNA sequencing datasets to identify new movement disorder-associated genes, by comparing DNA mutation frequencies in disease cases versus healthy control samples.
To study ALS, I will apply rigorous statistical approaches to the two largest DNA sequencing datasets of ALS patients. In addition to taking an agnostic approach looking at all genes in the genome, I will investigate sets of genes known to contribute to molecular pathways associated with ALS. Further, I will use our understanding of which regions of genes may have greater functional implications when mutated to guide my analyses. All novel genetic findings will be validated with cell-based experiments.
We are also currently initiating a consortium to create the largest DNA sequencing datasets yet available for ET by partnering with international research collaborators that also study patients with the disorder. I will take a leading role in this initiative and, following the DNA sequencing, I will apply similar analysis methods as described above in regards to ALS to identify and validate new genes contributing to the risk of ET.
The results of this study will provide further insights into what may be causing movement disorders on a molecular level, allowing for the identification of new treatment targets and genetic-sequencing-based early diagnostic and risk assessment tools. It is our goal to improve the diagnosis, prognosis, and outcomes for individuals facing movement disorders.
Competitiondate
202109
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Dilliott, Allison A
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~